Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation

Exclusion Criteria

• •Significant cardiac dysfunction.
• •Known active, recurrent, or chronic infection.
• •Active lupus or uncontrolled diabetes.
• •Prior treatment with rituximab within 6 months from SAR650984 administration.
• •Inadequate organ and bone marrow function at screening.
• •Pregnant or breastfeeding women or women who intend to become pregnant during participation in the study.
• •Known intolerance or hypersensitivity to any component of SAR650984 or pre-medications.
• •Participants who were not suitable for participation as judged by the Investigator.
• •The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.